Compare Citius Pharmaceuticals Inc (CTXR) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ecolab Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Ecolab Inc. trades at $270.86 (market cap $75.92B). The key difference: Ecolab Inc. is far larger — about 5185.8× Citius Pharmaceuticals Inc's market cap, and Ecolab Inc. pays a 1.08% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ECL | |
|---|---|---|
Market Cap | $14.64M | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $308.35 |
52-Week Low | $0.53 | $245.73 |
Enterprise Value | $10.86M | $84.66B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
ECL trades at $271.85, down 0.9% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.43, implying significant upside. Recent financials show revenue growth to $16.08B in 2025 and a net income margin of 12.8%, though earnings have been mixed with a Q2 2026 estimate of $2.08 pending. The company's acquisition of CoolIT for $4.75B strengthens its AI cooling portfolio, positioning it for long-term growth in high-tech markets.
The outlook for ECL is positive, supported by strong analyst buy ratings (75.68%) and strategic expansions, but risks include execution of recent acquisitions and cost pressures. The stock's current valuation multiples, such as a P/E of 36.79, suggest premium pricing that requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
